Alliance for Pandemic Preparedness

February 4, 2021

Safety, Tolerability, and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Healthy Adults Aged 60 Years and Older: A Randomised, Double-Blind, Placebo-Controlled, Phase 1/2 Clinical Trial

Category:

Topic:

Keywords (Tags):

In a randomized, double-blind, placebo-controlled phase 1/2 trial of the inactivated SARS-CoV-2 vaccine CoronaVac conducted among healthy, seronegative adults aged ≥60 years (n=421), all adverse reactions were mild or moderate, with injection site pain as the most frequently reported reaction (9%). Seroconversion after two doses was reported in at least 90% of all dosage groups and none in the placebo groups.

Wu et al. (Feb 3, 2021). Safety, Tolerability, and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Healthy Adults Aged 60 Years and Older: A Randomised, Double-Blind, Placebo-Controlled, Phase 1/2 Clinical Trial. The Lancet Infectious Diseases. https://www.thelancet.com/article/S1473-3099(20)30843-4/fulltext